ATE89006T1 - Expression von menschlichem proapolipoprotein a- 1. - Google Patents

Expression von menschlichem proapolipoprotein a- 1.

Info

Publication number
ATE89006T1
ATE89006T1 AT88870095T AT88870095T ATE89006T1 AT E89006 T1 ATE89006 T1 AT E89006T1 AT 88870095 T AT88870095 T AT 88870095T AT 88870095 T AT88870095 T AT 88870095T AT E89006 T1 ATE89006 T1 AT E89006T1
Authority
AT
Austria
Prior art keywords
proapolipoprotein
sequence
expression
expression vectors
dna sequences
Prior art date
Application number
AT88870095T
Other languages
English (en)
Inventor
Alex Bollen
Jean Gobert
Ernst Wuelfert
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Application granted granted Critical
Publication of ATE89006T1 publication Critical patent/ATE89006T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775Apolipopeptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
AT88870095T 1987-05-28 1988-05-24 Expression von menschlichem proapolipoprotein a- 1. ATE89006T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878712540A GB8712540D0 (en) 1987-05-28 1987-05-28 Expression of human proapolipoprotein a-i

Publications (1)

Publication Number Publication Date
ATE89006T1 true ATE89006T1 (de) 1993-05-15

Family

ID=10618034

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88870095T ATE89006T1 (de) 1987-05-28 1988-05-24 Expression von menschlichem proapolipoprotein a- 1.

Country Status (33)

Country Link
US (1) US5059528A (de)
EP (1) EP0293357B1 (de)
JP (1) JP2634193B2 (de)
KR (1) KR970000808B1 (de)
CN (1) CN1031892C (de)
AT (1) ATE89006T1 (de)
AU (1) AU615654B2 (de)
CA (1) CA1323851C (de)
CY (1) CY1809A (de)
CZ (1) CZ283648B6 (de)
DD (1) DD291093A5 (de)
DE (1) DE3880739T2 (de)
DK (1) DK175686B1 (de)
EG (1) EG19101A (de)
ES (1) ES2054878T3 (de)
FI (1) FI100056B (de)
GB (1) GB8712540D0 (de)
HK (1) HK137794A (de)
HU (1) HU204562B (de)
IE (1) IE62422B1 (de)
IL (1) IL86480A (de)
LT (1) LT3600B (de)
LV (1) LV5288A3 (de)
NO (1) NO179253C (de)
NZ (1) NZ224808A (de)
PL (1) PL158064B1 (de)
PT (1) PT87562B (de)
RU (1) RU2009198C1 (de)
SG (1) SG131594G (de)
SK (1) SK279166B6 (de)
SU (1) SU1834904A3 (de)
UA (1) UA19765A (de)
ZA (1) ZA883824B (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JP2606228B2 (ja) * 1987-09-18 1997-04-30 三菱化学株式会社 ヒトプロアポリポプロテインa−i様蛋白の産生法
DE68917379T2 (de) * 1988-05-31 1994-12-01 Mitsubishi Chem Ind Verfahren zur Herstellung von Proteinen, die ähnlich dem natürlich-menschlichen Apolipoprotein-E sind.
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
JP4236698B2 (ja) * 1990-11-26 2009-03-11 ジェネティックス インスティチュート,リミテッド ライアビリティ カンパニー 宿主細胞でのpaceの発現およびその使用法
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
DE69115926T2 (de) * 1990-11-30 1996-05-30 Monoclonetics Int Verfahren zur diagnose chronischer niedriger rückenschmerzen und nackenschmerzen
GB9508618D0 (en) * 1995-04-28 1995-06-14 Applied Research Systems Therapeutic protein
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5994061A (en) * 1995-09-29 1999-11-30 Queen's University At Kingston DNA constructs and methods for screening for increased expression of human apo AI gene
SE9603068D0 (sv) 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
KR100330355B1 (ko) * 1999-06-04 2002-04-01 장인순 회전유동발생 날개를 가진 덕트형 핵연료 집합체 지지격자
US20040047853A1 (en) * 2000-06-09 2004-03-11 Dahl Soren W Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
EP1341919A2 (de) * 2000-12-12 2003-09-10 Lexicon Genetics Incorporated Neuartige menschliche kinasen sowie anwendungen derselben
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 a-ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US7427662B2 (en) * 2005-02-01 2008-09-23 Baord Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
JP2009505652A (ja) * 2005-08-26 2009-02-12 セレニス セラピューティクス ホールディング エスア 乳酸菌においてアポリポタンパク質遺伝子生成物を生成するための組成物および方法
US20080293102A1 (en) * 2007-02-28 2008-11-27 Cerenis Therapeutics Holding, S.A. Compositions and methods for producing apolipoprotein
ES2727549T3 (es) * 2008-10-03 2019-10-17 Curna Inc Tratamiento de las enfermedades relacionadas con la apolipoproteína a1 por inhibición del transcrito antisentido natural a la apolipoproteína a1
ES2993911T3 (en) 2008-11-10 2025-01-13 Arbutus Biopharma Corp Novel lipids and compositions for the delivery of therapeutics
AU2010208035B2 (en) 2009-01-29 2016-06-23 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
NZ594995A (en) 2009-03-12 2013-06-28 Alnylam Pharmaceuticals Inc LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
CA2760776C (en) 2009-05-05 2019-07-09 Alnylam Pharmaceuticals, Inc. Lipid compositions for the delivery of therapeutic agents
WO2010129799A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
DK3431076T3 (da) 2009-06-10 2021-12-20 Arbutus Biopharma Corp Forbedret lipidformulering
AP3574A (en) 2009-08-14 2016-02-08 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US9687550B2 (en) 2009-12-07 2017-06-27 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
AU2010330814B2 (en) 2009-12-18 2017-01-12 Acuitas Therapeutics Inc. Methods and compositions for delivery of nucleic acids
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143362A1 (en) 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
CN103096875B (zh) 2010-06-03 2016-08-17 阿尔尼拉姆医药品有限公司 用于递送活性剂的生物可降解脂质
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
CN103370054A (zh) 2010-11-09 2013-10-23 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
WO2012099755A1 (en) 2011-01-11 2012-07-26 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
DK2673296T3 (en) 2011-02-07 2019-02-18 Cerenis Therapeutics Holding Sa LIPOPROTEIN COMPLEXES AND PREPARATION AND APPLICATIONS THEREOF
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換peg化脂質
US9610324B2 (en) * 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
RU2670614C9 (ru) * 2013-05-01 2018-11-23 Ионис Фармасьютикалз, Инк. Композиции и способы модулирования экспрессии hbv и ttr
EP2853259A1 (de) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Rekonstituierte hochdichte Lipoproteinzusammensetzung und Verwendungen davon
CN106488987A (zh) 2014-05-02 2017-03-08 塞勒尼斯医疗控股公司 Hdl疗法标志物
US11492616B2 (en) * 2016-10-27 2022-11-08 Institute Of Microbiology, Chinese Academy Of Sciences Method for modifying amino acid attenuator and use of same in production
US20190048049A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Sa Cargomers
US20190046608A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Sa Apomers
US11461863B2 (en) 2018-08-24 2022-10-04 Bright Marbles, Inc. Idea assessment and landscape mapping
US11081113B2 (en) 2018-08-24 2021-08-03 Bright Marbles, Inc. Idea scoring for creativity tool selection
US11189267B2 (en) 2018-08-24 2021-11-30 Bright Marbles, Inc. Intelligence-driven virtual assistant for automated idea documentation
US11164065B2 (en) 2018-08-24 2021-11-02 Bright Marbles, Inc. Ideation virtual assistant tools
US20240033322A1 (en) 2020-04-16 2024-02-01 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
MX2023003877A (es) 2020-10-01 2023-04-18 Abionyx Pharma Sa Composiciones que comprenden complejos basados en proteina de union a lipidos para usarse en el tratamiento de enfermedades oculares.
AU2022258815A1 (en) 2021-04-15 2023-10-19 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
EP4504150A1 (de) 2022-04-06 2025-02-12 Abionyx Pharma SA Verfahren zur behandlung von augenerkrankungen mit lipidbindenden komplexen auf proteinbasis
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
US20250360184A1 (en) 2022-06-10 2025-11-27 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
IL322074A (en) 2023-01-13 2025-09-01 Abionyx Pharma Sa Treatment using a lipid-binding protein molecule
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JPS6198998A (ja) 1984-10-18 1986-05-17 Matsushita Electric Ind Co Ltd 電動送風機
BE901119A (fr) 1984-11-23 1985-03-15 Wallone Region Procede de preparation de plasmides vecteurs capables de transformer un hote bacterien escherichia coli et d'y promouvoir et controler l'expression d'un adn heterologue.
DE3688418T2 (de) 1985-02-13 1993-08-26 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
GB8507833D0 (en) * 1985-03-26 1985-05-01 Biogen Nv Production of human somatomedin c
AU6522486A (en) 1985-10-04 1987-04-24 Biotechnology Research Partners Limited Recombinant apolipoproteins and methods
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
EP0269260A3 (de) * 1986-10-29 1988-06-22 Biotechnology Research Partners, Ltd. ApoAI-C-III-AIV, apoAII, apoB, apoCI und LDL-Rezeptor-Polymorphismus für genetischen Fingerabdruck und Atherosklerosevorhersage

Also Published As

Publication number Publication date
DK175686B1 (da) 2005-01-17
PT87562B (pt) 1992-09-30
DE3880739D1 (de) 1993-06-09
SG131594G (en) 1995-01-13
NO882341L (no) 1988-11-29
ZA883824B (en) 1989-02-22
US5059528A (en) 1991-10-22
SK363888A3 (en) 1998-07-08
CZ363888A3 (cs) 1998-02-18
PL158064B1 (pl) 1992-07-31
IE881597L (en) 1988-11-28
PL272698A1 (en) 1989-03-06
AU615654B2 (en) 1991-10-10
JPS6416589A (en) 1989-01-20
SK279166B6 (sk) 1998-07-08
HU204562B (en) 1992-01-28
IL86480A (en) 1992-08-18
LTIP828A (en) 1995-02-27
DK289688A (da) 1988-11-29
LT3600B (en) 1995-12-27
EG19101A (en) 1994-09-29
AU1672388A (en) 1988-12-01
EP0293357A1 (de) 1988-11-30
LV5288A3 (lv) 1993-10-10
NO882341D0 (no) 1988-05-27
NO179253B (no) 1996-05-28
CN1031892C (zh) 1996-05-29
ES2054878T3 (es) 1994-08-16
DE3880739T2 (de) 1993-08-19
HK137794A (en) 1994-12-16
KR880014110A (ko) 1988-12-22
RU2009198C1 (ru) 1994-03-15
KR970000808B1 (en) 1997-01-20
FI100056B (fi) 1997-09-15
DD291093A5 (de) 1991-06-20
DK289688D0 (da) 1988-05-27
GB8712540D0 (en) 1987-07-01
CZ283648B6 (cs) 1998-05-13
HUT47153A (en) 1989-01-30
IE62422B1 (en) 1995-02-08
FI882456L (fi) 1988-11-29
NZ224808A (en) 1990-01-29
PT87562A (pt) 1989-05-31
CY1809A (en) 1995-10-20
CN88103118A (zh) 1988-12-14
NO179253C (no) 1996-09-04
JP2634193B2 (ja) 1997-07-23
FI882456A0 (fi) 1988-05-25
IL86480A0 (en) 1988-11-15
UA19765A (uk) 1997-12-25
CA1323851C (en) 1993-11-02
EP0293357B1 (de) 1993-05-05
SU1834904A3 (ru) 1993-08-15

Similar Documents

Publication Publication Date Title
ATE89006T1 (de) Expression von menschlichem proapolipoprotein a- 1.
ES2059354T3 (es) Un metodo para producir un polipeptido.
DE3588255D1 (de) Klonierung und Expression von HTLV-III-DNS
NO177433C (no) DNA-vektor for ekspresjon av desulfatohirudin i gjær eller E.coli samt fremgangsmåte for fremstilling av desulfatohirudin og salter derav
DE69840230D1 (de) Polypeptide mit prolyldipeptidylaminopeptidase-aktivität und dafür kodierende nukleinsäuren
NO177570B (no) Fremgangsmåte ved fremstilling av peptider med fibronektinbindende egenskaper, mikroorganisme og DNA-sekvens som koder for peptider med fibronektinbindende egenskaper
NO930428L (no) Proteinstrukturen til plantetoksingelonin
ATE166390T1 (de) Anti-katze immundefiziensvirus (fiv) impfstoffe
PE20000759A1 (es) Gen de la citocroma oxidasa de hidroquinona del tipo bd
DK27097A (da) Minactivin og fremgangsmåde til fremstilling deraf
DK0422217T3 (da) Human, rekombinant, placental ribonucleaseinhibitor og fremgangsmåde til produktion
DE3856392D1 (de) Klonierung von Malaria-spezifischen DNA-Sequenzen:Isolierung des Gens für das 140 kd Protein
ATE80181T1 (de) Zur wirksamen gen-expression faehiger vektor und verwendung desselben.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee